Revvity, Inc. (RVTY) Stock Analysis
Is RVTY a good investment?
Revvity, Inc. (RVTY) has a Plutrex AI rating of 72.5/100 as of May 26, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: Industry-leading profitability with 19.0% operating margin vs industry losses of -5.6%. Main concern: PEG ratio of 1.85 indicates overvaluation with growth not justifying 47.8x PE premium.
Investment Summary
RVTY presents a quality company with exceptional operational metrics trading at premium valuations. Key fundamentals: ROE of 3.2% (poor absolute but +101% vs industry -231%), operating margin of 19.0% (+2,464% vs industry -5.6%), PE ratio of 47.8x (29.5% premium to industry 36.9x), and PEG of 1.85 (overvalued but 10.5% discount to industry 2.07). Strong Q4 earnings beat with 19.7% YoY growth and positive 2026 guidance offset concerns about modest 5.9% revenue growth vs industry 18.4%. Conservative debt-to-equity of 0.38 and $920M cash provide stability in volatile biotech sector.
Key Strengths
- Industry-leading profitability with 19.0% operating margin vs industry losses of -5.6%
- Strong Q4 earnings beat with 19.7% YoY growth and positive 2026 guidance above estimates
- Conservative balance sheet with 0.38 debt-to-equity ratio and $920M cash providing stability
Key Concerns
- PEG ratio of 1.85 indicates overvaluation with growth not justifying 47.8x PE premium
- Revenue growth of 5.9% significantly lags industry average of 18.4% raising competitive concerns
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
RVTY demonstrates mixed fundamentals with clear quality leadership offset by valuation concerns. Profitability metrics show excellence: gross margin 46.7% (+6.1% vs industry 44.1%), operating margin 19.0% vs industry losses of -5.6%, net margin 8.4% vs industry -12.6%. However, ROE of 3.2% remains concerningly low despite massive industry outperformance. Growth metrics disappoint with revenue growth 5.9% (vs industry 18.4%) and forward EPS growth 10.7% (vs industry 35.1%). Valuation shows PE 47.8x and PEG 1.85 indicating overvaluation, though analyst target $117.88 suggests 18% upside. Financial health strong with debt-to-equity 0.38 and free cash flow $555M.
News Sentiment
Revvity is riding high after delivering a stellar fourth quarter that has investors buzzing about the life sciences company's prospects. The biotech services firm crushed earnings expectations with a remarkable 19.7% year-over-year growth, prompting headlines like 'Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter' and 'Revvity Stock Up as Q4 Earnings Beat, Revenues In Line With Estimates.' The company's strong performance comes despite facing headwinds from NIH funding challenges that have pressured some research customers. What's particularly impressive is how Revvity has managed to offset regional weakness in China through successful geographic diversification, with non-China markets picking up the slack. The company's diagnostics business continues to show strength, benefiting from rising demand from pharmaceutical and biotech customers. Adding to investor confidence, Revvity's board declared a regular quarterly dividend of $0.07 per share, signaling management's confidence in the business. Looking ahead, the company's 2026 guidance came in above Wall Street estimates, suggesting the momentum from Q4 could continue. For investors, this represents a company successfully navigating a challenging environment while positioning itself for sustained growth in the expanding life sciences market.
Risk Assessment
Primary risks include valuation compression if growth disappoints (PEG 1.85 vulnerable), competitive pressure in diagnostics market evidenced by lagging revenue growth, and NIH funding challenges affecting research customers. Mitigation through conservative position sizing, entry below current price, and stop-loss at $87.50 (7.5% below entry) to limit downside.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is RVTY a halal stock?
No, Revvity, Inc. (RVTY) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for RVTY?
Revvity, Inc. (RVTY) has a Plutrex AI rating of 72.5/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is RVTY a good investment?
According to Plutrex AI, RVTY has a Buy rating (72.5/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in RVTY?
US stocks like RVTY can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in RVTY?
Plutrex AI identifies the main risks for RVTY by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.